PURPOSE: To better understand the histogenesis of ocular hemangioblastomas associated with von Hippel-Lindau (VHL) disease. METHODS: We found that co-expression of Epo and EpoR may mediate developmental stagnation and induce proliferation of hemangioblastoma. All lesions were frozen and/or fixed in formalin and embedded in paraffin. The specimens were sectioned and subjected to routine histology, immunohistochemistry and molecular analyses. Avidin-biotin-complex immunoperoxidase was used to evaluate the expression of erythropoietin (Epo), Epo receptor (EpoR), CD31, CD34, CD117, and CD133. Ocular hemangioblastoma cells were microdissected in order to determine expression of Epo and EpoR transcripts using reverse transcription-polymerase chain reaction. RESULTS: Tumorlet-like cells were identified in retinal and optic nerve hemangioblastomas. Co-expression of Epo and EpoR at both protein and messenger levels was detected in many hemangioblastoma cells. In addition, ocular VHL lesions expressed several stem cell markers including CD133 to various degrees. CONCLUSIONS: The data suggest that VHL disease-associated ocular hemangioblastomas are comprised of developmentally arrested stem cells including hemangioblasts, endothelial, and neuronal progenitor cells. We found that co-expression of Epo and EpoR may not only mediate developmental stagnation, but may also induce proliferation. Suppression of the growth of AC133/CD133 positive stem cells might be considered as one of the therapeutic targets for VHL-associated hemangioblastoma.
PURPOSE: To better understand the histogenesis of ocular hemangioblastomas associated with von Hippel-Lindau (VHL) disease. METHODS: We found that co-expression of Epo and EpoR may mediate developmental stagnation and induce proliferation of hemangioblastoma. All lesions were frozen and/or fixed in formalin and embedded in paraffin. The specimens were sectioned and subjected to routine histology, immunohistochemistry and molecular analyses. Avidin-biotin-complex immunoperoxidase was used to evaluate the expression of erythropoietin (Epo), Epo receptor (EpoR), CD31, CD34, CD117, and CD133. Ocular hemangioblastoma cells were microdissected in order to determine expression of Epo and EpoR transcripts using reverse transcription-polymerase chain reaction. RESULTS: Tumorlet-like cells were identified in retinal and optic nerve hemangioblastomas. Co-expression of Epo and EpoR at both protein and messenger levels was detected in many hemangioblastoma cells. In addition, ocular VHL lesions expressed several stem cell markers including CD133 to various degrees. CONCLUSIONS: The data suggest that VHL disease-associated ocular hemangioblastomas are comprised of developmentally arrested stem cells including hemangioblasts, endothelial, and neuronal progenitor cells. We found that co-expression of Epo and EpoR may not only mediate developmental stagnation, but may also induce proliferation. Suppression of the growth of AC133/CD133 positive stem cells might be considered as one of the therapeutic targets for VHL-associated hemangioblastoma.
Authors: Jean François Girmens; Ali Erginay; Pascale Massin; Paul Scigalla; Alain Gaudric; Stéphane Richard Journal: Am J Ophthalmol Date: 2003-07 Impact factor: 5.258
Authors: Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal Journal: Am J Hum Genet Date: 2003-07-03 Impact factor: 11.025
Authors: Lloyd Paul Aiello; Daniel J George; Mark T Cahill; Jun S Wong; Jerry Cavallerano; Alison L Hannah; William G Kaelin Journal: Ophthalmology Date: 2002-09 Impact factor: 12.079
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Min Zhou; Defen Shen; James E Head; Emily Y Chew; Patricia Chévez-Barrios; W Richard Green; Chi-Chao Chan Journal: Mol Vis Date: 2007-11-15 Impact factor: 2.367
Authors: Marc Diensthuber; Marc Potinius; Thomas Rodt; Alexandru C Stan; Hans-J Welkoborsky; Madjid Samii; Jonas Schreyögg; Thomas Lenarz; Timo Stöver Journal: J Neurooncol Date: 2008-04-23 Impact factor: 4.130
Authors: Murilo Rodrigues; Nicholas T Iliff; Charles G Eberhart; Silvia Montaner; Akrit Sodhi Journal: Can J Ophthalmol Date: 2013-08 Impact factor: 1.882